Patents by Inventor David Suhy

David Suhy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
    Publication number: 20250064973
    Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
    Type: Application
    Filed: August 24, 2023
    Publication date: February 27, 2025
    Inventors: David SUHY, Paul ESCARPE, Cyriac ROEDING, Justin LIN, Alex HARWIG, Shireen RUDINA, Leland Harrison HARTWELL
  • METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
    Publication number: 20250060367
    Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
    Type: Application
    Filed: August 18, 2023
    Publication date: February 20, 2025
    Inventors: David SUHY, Paul ESCARPE, Cyriac ROEDING, Justin LIN, Alex HARWIG, Shireen RUDINA, Leland Harrison HARTWELL
  • Methods and compositions for synthetic biomarkers
    Patent number: 12060613
    Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
    Type: Grant
    Filed: March 31, 2021
    Date of Patent: August 13, 2024
    Assignee: EARLI Inc.
    Inventors: David Suhy, Paul Escarpe, Cyriac Roeding, Justin Lin, Alex Harwig, Shireen Rudina, Leland Harrison Hartwell
  • Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
    Patent number: 11932852
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR) and short hairpin RNA (shRNA), for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto. The present disclosure also relates to the use of the RNAi reagents in combination with PABPN1 replacment reagents, such as constructs which encode functional PABPN1 protein, for treatment of OPMD, compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Grant
    Filed: September 1, 2021
    Date of Patent: March 19, 2024
    Assignee: Benitec IP Holdings Inc.
    Inventors: Vanessa Strings-Ufombah, David Suhy
  • REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
    Publication number: 20230093951
    Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.
    Type: Application
    Filed: November 18, 2022
    Publication date: March 30, 2023
    Inventors: Tin MAO, David SUHY
  • COMPOSITIONS AND METHODS FOR TREATING NEUROFIBROMATIC DISORDERS
    Publication number: 20230056226
    Abstract: Compositions and methods for treating neurofibromatic disorders are provided herein, such as expressing Merlin protein or a functional fragment thereof from a viral vector.
    Type: Application
    Filed: June 8, 2022
    Publication date: February 23, 2023
    Inventors: Scott R. Plotkin, Michael Wootton, David Suhy, Shih-chu Kao
  • Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
    Patent number: 11535851
    Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV. The reagents are artificial miRNA (shmiRNA) used alone or in combination with additional shmiRNA or shRNA.
    Type: Grant
    Filed: May 5, 2017
    Date of Patent: December 27, 2022
    Assignee: Benitec IP Holdings Inc.
    Inventors: Tin Mao, David Suhy
  • METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
    Publication number: 20220275451
    Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
    Type: Application
    Filed: October 5, 2021
    Publication date: September 1, 2022
    Inventors: David SUHY, Paul ESCARPE, Cyriac ROEDING, Justin LIN, Alex HARWIG, Shireen RUDINA
  • Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)
    Publication number: 20220106594
    Abstract: The present disclosure relates to methods of administering a gene therapy construct comprising RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR), in combination with PABPN1 replacement reagents, such as polynucleotides which encode functional PABPN1 protein which are not targeted by the RNAi reagents, for treatment of oculopharyngeal muscular dystrophy (OPMD) in individuals suffering from OPMD or which are predisposed thereto. In certain aspects the method comprises direct injection to a subject's pharyngeal muscles.
    Type: Application
    Filed: October 17, 2019
    Publication date: April 7, 2022
    Inventors: Vanessa Strings-Ufombah, David Suhy
  • Compositions and Methods for Treating Oculopharyngeal Muscular Dystrophy (OPMD)
    Publication number: 20220098614
    Abstract: The present disclosure relates to modified adeno-associated virus (AAV) delivery vectors comprising ‘silence and replace’ DNA constructs, compositions comprising same, and the use of the modified AAV and compositions to treat oculopharyngeal muscular dystrophy (OPMD) in individuals suffering from OPMD or which are predisposed thereto. In particular, the disclosure relates to AAV having a capsid protein with a modified subunit 1 (VP1) and comprising a ‘silence and replace’ DNA construct, wherein the ‘silence and replace’ DNA construct comprises (i) a DNA-directed RNAi (ddRNAi) construct encoding short hairpin microRNA (shmiR) targeting PABPN1 causative of OPMD and (ii) a PABPN1 construct encoding functional PABPN1 protein having a mRNA transcript which is not targeted by the shmiRs at (i). The present disclosure also relates to the methods of treating OPMD comprising direct injection of an AAV of the disclosure to a subject's pharyngeal muscles.
    Type: Application
    Filed: February 28, 2020
    Publication date: March 31, 2022
    Inventors: Vanessa Strings-Ufombah, David Suhy, Shih-Chu Kao, Petrus W. Roelvink
  • Reagents for Treatment of Oculopharyngeal Muscular Dystrophy (OPMD) and Use Thereof
    Publication number: 20220056446
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR) and short hairpin RNA (shRNA), for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto. The present disclosure also relates to the use of the RNAi reagents in combination with PABPN1 replacement reagents, such as constructs which encode functional PABPN1 protein, for treatment of OPMD, compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Application
    Filed: September 1, 2021
    Publication date: February 24, 2022
    Inventors: Vanessa Strings-Ufombah, David Suhy
  • Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
    Patent number: 11234994
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: February 1, 2022
    Assignee: Benitec Biopharma Limited
    Inventors: David Suhy, Michael Graham, Capucine Trollet, Alberto Malerba, John George Dickson
  • Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
    Patent number: 11142765
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR) and short hairpin RNA (shRNA), for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto. The present disclosure also relates to the use of the RNAi reagents in combination with PABPN1 replacement reagents, such as constructs which encode functional PABPN1 protein, for treatment of OPMD, compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: October 12, 2021
    Assignee: Benitec IP Holdings, Inc.
    Inventors: Vanessa Strings-Ufombah, David Suhy
  • METHODS AND COMPOSITIONS FOR SYNTHETIC BIOMARKERS
    Publication number: 20210277474
    Abstract: The present disclosure encompasses embodiments of nucleic acids comprising genetic elements which are useful for the detection of diseased cells.
    Type: Application
    Filed: March 31, 2021
    Publication date: September 9, 2021
    Inventors: David SUHY, Paul ESCARPE, Cyriac ROEDING, Justin LIN, Alex HARWIG, Shireen RUDINA, Leland Harrison HARTWELL
  • REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
    Publication number: 20210177885
    Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.
    Type: Application
    Filed: December 16, 2020
    Publication date: June 17, 2021
    Inventors: TIN MAO, SHIH-CHU KAO, DAVID SUHY, MICHAEL GRAHAM
  • Reagents for treatment of hepatitis B virus (HBV) infection and use thereof
    Patent number: 10898505
    Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: January 26, 2021
    Assignee: Benitec Biopharma Limited
    Inventors: Tin Mao, Shih-Chu Kao, David Suhy, Michael Graham
  • REAGENTS FOR TREATMENT OF OCULOPHARYNGEAL MUSCULAR DYSTROPHY (OPMD) AND USE THEREOF
    Publication number: 20200138849
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Application
    Filed: April 13, 2017
    Publication date: May 7, 2020
    Inventors: David SUHY, Michael GRAHAM, Capucine TROLLET, Alberto MALERBA, George J. Dickson
  • REAGENTS FOR TREATMENT OF HEPATITIS B VIRUS (HBV) INFECTION AND USE THEREOF
    Publication number: 20190338285
    Abstract: This disclosure relates to RNA interference (RNAi) reagents for treatment of hepatitis B virus (HBV) infection, compositions comprising same, and use thereof to treat individuals infected with HBV. The reagents are artificial miRNA (shmiRNA) used alone or in combination with additional shmiRNA or shRNA.
    Type: Application
    Filed: May 5, 2017
    Publication date: November 7, 2019
    Applicant: BENITEC BIOPHARMA LIMITED
    Inventors: Tin MAO, David SUHY
  • Reagents for treatment of oculopharyngeal muscular dystrophy (OPMD) and use thereof
    Publication number: 20190330629
    Abstract: The present disclosure relates to RNA interference (RNAi) reagents, such as short hairpin microRNA (shmiR) and short hairpin RNA (shRNA), for treatment of oculopharyngeal muscular dystrophy (OPMD), compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto. The present disclosure also relates to the use of the RNAi reagents in combination with PABPN1 replacement reagents, such as constructs which encode functional PABPN1 protein, for treatment of OPMD, compositions comprising same, and use thereof to treat individuals suffering from OPMD or which are predisposed thereto.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 31, 2019
    Inventors: Vanessa Strings-Ufombah, David Suhy
  • REAGENTS FOR PRODUCING T-CELLS WITH NON-FUNCTIONAL T-CELL RECEPTORS (TCRs) COMPOSITIONS COMPRISING SAME AND USE THEREOF
    Publication number: 20190309307
    Abstract: The present disclosure relates to reagents for producing T-cells comprising non-functional T-cell receptors (TCR), including T-cells which also express chimeric antigen receptors (CAR), i.e., CAR-T cells, compositions comprising said reagents and T-cells, and uses of said CAR-T cells in therapy e.g., adoptive therapy.
    Type: Application
    Filed: September 14, 2017
    Publication date: October 10, 2019
    Inventors: Patty Bertha GARCIA, Vanessa STRINGS-UFOMBAH, Peter ROELVINK, Michael GRAHAM, David SUHY